Non-prescription Therapeutics

Weingarden, Alexa R.; Ko, Cynthia W.

doi:10.14309/ajg.0000000000002578

Am J Gastroenterol

2024

DOI: 10.14309/ajg.0000000000002578

|View full text |Cite

Non-prescription Therapeutics

Alexa R. Weingarden,

Cynthia W. Ko

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Nondiagnostic advancements in revolutionizing lactose intolerance: A minireview for health sciences

Tariq,

Qadeer,

Anjum

et al. 2024

Hybrid Advances

View full text Add to dashboard Cite

Nondiagnostic advancements in revolutionizing lactose intolerance: A minireview for health sciences

Tariq,

Qadeer,

Anjum

et al. 2024

Hybrid Advances

View full text Add to dashboard Cite

Current and future microbiome-based therapies in inflammatory bowel disease

Montrose,

Kurada,

Fischer

2024

Current Opinion in Gastroenterology

View full text Add to dashboard Cite

Purpose of review The role of the microbiome and dysbiosis is increasingly recognized in the pathogenesis of inflammatory bowel disease (IBD). Intestinal microbiota transplant (IMT), previously termed fecal microbiota transplant has demonstrated efficacy in restoring a healthy microbiome and promoting gut health in recurrent Clostridioides difficile infection. Several randomized trials (RCTs) highlighted IMT's potential in treating ulcerative colitis, while smaller studies reported on its application in managing Crohn's disease and pouchitis. Recent findings This review delves into the current understanding of dysbiosis in IBD, highlighting the distinctions in the microbiota of patients with IBD compared to healthy controls. It explores the mechanisms by which IMT can restore a healthy microbiome and provides a focused analysis of recent RCTs using IMT for inducing and maintaining remission in IBD. Lastly, we discuss the current knowledge gaps that limit its widespread use. Summary The body of evidence supporting the use of IMT in IBD is growing. The lack of a standardized protocol impedes its application beyond clinical trials. Further research is needed to identify patient profile and disease phenotypes that benefit from IMT, to delineate key donor characteristics, optimize the delivery route, dosage, and frequency.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Non-prescription Therapeutics

Cited by 2 publications

References 100 publications

Nondiagnostic advancements in revolutionizing lactose intolerance: A minireview for health sciences

Nondiagnostic advancements in revolutionizing lactose intolerance: A minireview for health sciences

Current and future microbiome-based therapies in inflammatory bowel disease

Contact Info

Product

Resources

About